MERS-CoV spike protein: a key target for antivirals.
Identifieur interne : 000E55 ( PubMed/Curation ); précédent : 000E54; suivant : 000E56MERS-CoV spike protein: a key target for antivirals.
Auteurs : Lanying Du [États-Unis] ; Yang Yang [États-Unis] ; Yusen Zhou [République populaire de Chine] ; Lu Lu [République populaire de Chine] ; Fang Li [États-Unis] ; Shibo Jiang [États-Unis]Source :
- Expert opinion on therapeutic targets [ 1744-7631 ] ; 2017.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (pharmacologie), Anticorps neutralisants (pharmacologie), Antiviraux (pharmacologie), Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient (), Humains, Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Peptides (pharmacologie), Pénétration virale ().
- MESH :
- pharmacologie : Anticorps monoclonaux, Anticorps neutralisants, Antiviraux, Peptides.
- traitement médicamenteux : Infections à coronavirus.
- virologie : Infections à coronavirus.
- Animaux, Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Pénétration virale.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (pharmacology), Antibodies, Neutralizing (pharmacology), Antiviral Agents (pharmacology), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Drug Design, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects), Peptides (pharmacology), Virus Internalization (drug effects).
- MESH :
- chemical , pharmacology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antiviral Agents, Peptides.
- drug effects : Middle East Respiratory Syndrome Coronavirus, Virus Internalization.
- drug therapy : Coronavirus Infections.
- virology : Coronavirus Infections.
- Animals, Drug Design, Humans.
Abstract
The continual Middle East respiratory syndrome (MERS) threat highlights the importance of developing effective antiviral therapeutics to prevent and treat MERS coronavirus (MERS-CoV) infection. A surface spike (S) protein guides MERS-CoV entry into host cells by binding to cellular receptor dipeptidyl peptidase-4 (DPP4), followed by fusion between virus and host cell membranes. MERS-CoV S protein represents a key target for developing therapeutics to block viral entry and inhibit membrane fusion. Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides. Expert opinion: No anti-MERS-CoV therapeutic is approved for human use. Several S-targeting neutralizing mAbs and peptides have demonstrated efficacy against MERS-CoV infection, providing feasibility for development. Generally, human neutralizing mAbs targeting RBD are more potent than those targeting other regions of S protein. However, emergence of escape mutant viruses and mAb's limitations make it necessary for combining neutralizing mAbs recognizing different neutralizing epitopes and engineering them with improved efficacy and reduced cost. Optimization of the peptide sequences is expected to produce next-generation anti-MERS-CoV peptides with improved potency.
DOI: 10.1080/14728222.2017.1271415
PubMed: 27936982
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E55
Links to Exploration step
pubmed:27936982Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MERS-CoV spike protein: a key target for antivirals.</title>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation wicri:level="1"><nlm:affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Yang" sort="Yang, Yang" uniqKey="Yang Y" first="Yang" last="Yang">Yang Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
<affiliation wicri:level="1"><nlm:affiliation>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Fang" sort="Li, Fang" uniqKey="Li F" first="Fang" last="Li">Fang Li</name>
<affiliation wicri:level="1"><nlm:affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation wicri:level="1"><nlm:affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:27936982</idno>
<idno type="pmid">27936982</idno>
<idno type="doi">10.1080/14728222.2017.1271415</idno>
<idno type="wicri:Area/PubMed/Corpus">000E55</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E55</idno>
<idno type="wicri:Area/PubMed/Curation">000E55</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">MERS-CoV spike protein: a key target for antivirals.</title>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation wicri:level="1"><nlm:affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Yang" sort="Yang, Yang" uniqKey="Yang Y" first="Yang" last="Yang">Yang Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
<affiliation wicri:level="1"><nlm:affiliation>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Fang" sort="Li, Fang" uniqKey="Li F" first="Fang" last="Li">Fang Li</name>
<affiliation wicri:level="1"><nlm:affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation wicri:level="1"><nlm:affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Expert opinion on therapeutic targets</title>
<idno type="eISSN">1744-7631</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (pharmacology)</term>
<term>Antibodies, Neutralizing (pharmacology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Peptides (pharmacology)</term>
<term>Virus Internalization (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps monoclonaux (pharmacologie)</term>
<term>Anticorps neutralisants (pharmacologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Conception de médicament</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Peptides (pharmacologie)</term>
<term>Pénétration virale ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antiviral Agents</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Virus Internalization</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Anticorps neutralisants</term>
<term>Antiviraux</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Conception de médicament</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Pénétration virale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The continual Middle East respiratory syndrome (MERS) threat highlights the importance of developing effective antiviral therapeutics to prevent and treat MERS coronavirus (MERS-CoV) infection. A surface spike (S) protein guides MERS-CoV entry into host cells by binding to cellular receptor dipeptidyl peptidase-4 (DPP4), followed by fusion between virus and host cell membranes. MERS-CoV S protein represents a key target for developing therapeutics to block viral entry and inhibit membrane fusion. Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides. Expert opinion: No anti-MERS-CoV therapeutic is approved for human use. Several S-targeting neutralizing mAbs and peptides have demonstrated efficacy against MERS-CoV infection, providing feasibility for development. Generally, human neutralizing mAbs targeting RBD are more potent than those targeting other regions of S protein. However, emergence of escape mutant viruses and mAb's limitations make it necessary for combining neutralizing mAbs recognizing different neutralizing epitopes and engineering them with improved efficacy and reduced cost. Optimization of the peptide sequences is expected to produce next-generation anti-MERS-CoV peptides with improved potency.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27936982</PMID>
<DateCompleted><Year>2017</Year>
<Month>06</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7631</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>21</Volume>
<Issue>2</Issue>
<PubDate><Year>2017</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Expert opinion on therapeutic targets</Title>
<ISOAbbreviation>Expert Opin. Ther. Targets</ISOAbbreviation>
</Journal>
<ArticleTitle>MERS-CoV spike protein: a key target for antivirals.</ArticleTitle>
<Pagination><MedlinePgn>131-143</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/14728222.2017.1271415</ELocationID>
<Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The continual Middle East respiratory syndrome (MERS) threat highlights the importance of developing effective antiviral therapeutics to prevent and treat MERS coronavirus (MERS-CoV) infection. A surface spike (S) protein guides MERS-CoV entry into host cells by binding to cellular receptor dipeptidyl peptidase-4 (DPP4), followed by fusion between virus and host cell membranes. MERS-CoV S protein represents a key target for developing therapeutics to block viral entry and inhibit membrane fusion. Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides. Expert opinion: No anti-MERS-CoV therapeutic is approved for human use. Several S-targeting neutralizing mAbs and peptides have demonstrated efficacy against MERS-CoV infection, providing feasibility for development. Generally, human neutralizing mAbs targeting RBD are more potent than those targeting other regions of S protein. However, emergence of escape mutant viruses and mAb's limitations make it necessary for combining neutralizing mAbs recognizing different neutralizing epitopes and engineering them with improved efficacy and reduced cost. Optimization of the peptide sequences is expected to produce next-generation anti-MERS-CoV peptides with improved potency.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName>
<ForeName>Lanying</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Yusen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Fang</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Shibo</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai , China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI089728</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI098775</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI110700</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI109094</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Expert Opin Ther Targets</MedlineTA>
<NlmUniqueID>101127833</NlmUniqueID>
<ISSNLinking>1472-8222</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">MERS</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">membrane fusion</Keyword>
<Keyword MajorTopicYN="Y">monoclonal antibodies</Keyword>
<Keyword MajorTopicYN="Y">peptides</Keyword>
<Keyword MajorTopicYN="Y">receptor-binding domain</Keyword>
<Keyword MajorTopicYN="Y">spike protein</Keyword>
<Keyword MajorTopicYN="Y">therapeutics</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>12</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>12</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27936982</ArticleId>
<ArticleId IdType="doi">10.1080/14728222.2017.1271415</ArticleId>
<ArticleId IdType="pmc">PMC5457961</ArticleId>
<ArticleId IdType="mid">NIHMS861913</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Sci Rep. 2015 Aug 18;5:13133</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26281793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jun;88(12):7045-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24719424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Jul;20(7):1231-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24964193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2013 Jun 4;127(22):2222-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23733968</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Nov;19(11):1819-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24206838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Dec;20(12 ):1999-2005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25418529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Sep;87(17):9939-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23824801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Curr. 2014 Dec 18;6:null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25685622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2016 Sep 3;388(10048):994-1001</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27402381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Feb;89(4):1954-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25428871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367 (19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2014 Sep 26;6(9):3683-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25256397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Sep 15;6:8223</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26370782</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Yonsei Med J. 2015 Sep;56(5):1174-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26256957</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Oct;87(19):10777-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23903833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2015 Oct;39:7-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26275845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Angew Chem Int Ed Engl. 2002 Aug 16;41(16):2937-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12203417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Sep;89(17):9119-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26063432</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2010 May;10(5):345-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20414207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15150417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2014 Apr 30;6(234):234ra59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24778414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2015 Feb 1;60(3):369-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25323704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Dec;87(23):12552-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24027332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Feb;88(3):1834-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24257613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2013 Jun 29;381(9885):2265-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23727167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Oct;19(10):1697-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24050621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 2006 Dec 26;45(51):15205-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17176042</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Jun;20(6):1012-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24857749</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24778221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transbound Emerg Dis. 2017 Apr;64(2):344-353</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26256102</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Jun 26;370(26):2499-505</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24896817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Host Microbe. 2014 Sep 10;16(3):328-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25211075</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 Feb 22;6:21878</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26899616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2014;5:3067</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24473083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2016 Jun 03;13:87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27255185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Oct 03;8(10):e76469</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24098509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2015 Jun 17;4:e37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26954884</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 May;80(9):4211-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16611880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2016 May 15;213(10 ):1557-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26941283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2015 Sep 08;6(5):e01280-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26350969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 Aug 19;6:31629</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27538452</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Mar 15;211(6):889-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25057042</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Nov 19;279(47):49414-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15345712</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jul;88(14):7796-805</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24789777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2012 Nov;1(11):e35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26038405</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Mol Med. 2015 Aug 28;47:e181</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26315600</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2015 Apr;21(4):699-701</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25811546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2016 Aug;132:141-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27312105</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Aug;88(16):9220-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24899185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2015 May-Jun;13(3):269-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25858100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2014 Mar;95(Pt 3):614-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24362959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2013 Sep 10;4(5):e00650-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24023385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2014 Dec 19;194:200-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25451066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24043791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2012 Oct 04;17(40):20290</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23078800</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Health. 2015 Jul 21;37:e2015033</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26212508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2014 Jun;13(6):761-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24766432</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2015 Nov;25(11):1237-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26391698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Dec 15;212(12 ):1894-903</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26164863</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 2009 May;157(2):220-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19459844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2012 Dec;65(6):477-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23072791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dev Ctries. 2015 Jul 04;9(6):543-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26142661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Jun;20(6):1049-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24856660</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Feb;14 (2):140-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24355866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jul 16;279(29):30514-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15123674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2015 Aug;17(8):542-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26107106</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26124093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2016 Apr 22;291(17 ):9218-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26953343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2015 Sep 5;386(9997):995-1007</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26049252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2010 Apr;9(4):325-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20305665</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Dec;87(24):13134-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24067982</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Dec;87(24):13892-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24067970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Feb;81(4):1574-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17121802</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2012 Nov 20;3(6):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Microbiol. 2015 Aug;23(8):468-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26206723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Chemother. 2016 Jun;48(2):75-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27433377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12516-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25114257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Oct 07;90(1):57-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26446606</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25288733</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 May;88(9):4953-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24554656</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2015 Sep;38:65-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26216766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2014 May 2;344(6183):457-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24786052</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2016 Mar;490:49-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26828465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Aug;20(8):1370-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25062254</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 May;87(10):5502-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23468491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26216974</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000E55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:27936982 |texte= MERS-CoV spike protein: a key target for antivirals. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27936982" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |